Accurant Biotech is an outsourcing organization (CRO) focusing on immune-based and cell-based method development, method validation and sample analysis in support of clinical and preclinical trials for biological drug development. We provide one-stop service of biological analysis for global pharma and biotech companies. Our services include preparation of large molecule bioanalysis reagent, development and validation of bioanalytical methodology and sample analysis in compliance with GLP regulations. 

The founder team is composed of industry experts, some of them are oversea researchers with years of experience in well-known pharmaceutical companies, large molecule biologics bioanalysis expert, or long-standing committee members of several relevant associations in China and US. They participated in the writing of influential guidance white papers in the bioanalysis industry in US and ' Guidelines for biological sample analysis method verification' in Chinese pharmacopoeia of 2015. Accurant Biotech Ningbo site was established in Ningbo High-Tech zone in October 2017 with a registered capital of 10 million RMB. Through the elite talent program, the company was endorsed by the government of Ningbo with incubator fund and laboratory facilities in 2017. In 2018, Accurant was awarded the top 10 “Most Investable Startup” in Ningbo. 

Accurant Biotech has operations in 3 different cities in China and US. The global operation setup enables Accurant Biotech to provide streamline services for multi-site clinical trials to support biologics drug development.